33.00
0.08 (0.24%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bullish |
Biotechnology (Global) | Bearish | Bullish | |
Stock | Agios Pharmaceuticals, Inc. | Bearish | Bearish |
Analyst Consensus
2 Hold
Avg. Price @ Call: 33.77
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
52 Weeks Range |
19.80 - 35.50
|
|
Price Target Range | ||
High | 33.00 (Goldman Sachs, 0.00%) | Hold |
Median | 33.00 (0.00%) | |
Low | 30.00 (JP Morgan, -9.09%) | Hold |
Average | 35.00 (6.06%) | |
Total | 2 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Goldman Sachs | 03 May 2024 | 33.00 (0.00%) | Hold | 34.54 |
JP Morgan | 23 Feb 2024 | 30.00 (-9.09%) | Hold | 32.99 |
No data within this time range.
Date | Type | Details |
---|---|---|
14 May 2024 | Announcement | Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress |
06 May 2024 | Announcement | Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 |
03 May 2024 | Announcement | Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 |
02 May 2024 | Announcement | Agios Reports Business Highlights and First Quarter 2024 Financial Results |
18 Apr 2024 | Announcement | Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 |
09 Apr 2024 | Announcement | Agios Publishes 2024 Environmental, Social and Governance (ESG) Report |
05 Mar 2024 | Announcement | Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 |
22 Feb 2024 | Announcement | Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |